ALARIC
A Phase 1 trial assessing the treatment of AL Amyloid (relapsed/refractory to previous therapy) with CAR T cells

Phase 1 rolling 6 trial design evaluating safety of a novel D8 alone and of D8/CAT CAR T cells in patients with AL amyloid. This trial consists of two initial cohorts: Cohort 1 assesses D8 CAR T cells [...]

Area: Advanced therapies

Phase: Phase I

Status: Active (recruiting)

ALLCAR19
Immunotherapy for high risk/relapsed CD19+ Acute Lymphoblastic Leukaemia using CAR T-cells to target CD19

ALLCAR19 is a multi-site, non-randomised phase I trial in adults with high risk or refractory CD19+ B-cell Acute Lymphoblastic Leukaemia. The Advanced Therapy Investigational Medicinal Product (ATIMP) [...]

Area: Advanced therapies

Phase: Phase I

Status: Active (recruiting)

CARD
CAR19 Donor Lymphocytes for relapsed CD19+ malignancies following allogeneic transplantation

CARD is a single centre, single arm intra-patient dose-escalation phase I study in adults with relapsed CD19+ malignancies following allogeneic stem cell transplantation. The Advanced Therapies Invest [...]

Area: Advanced therapies

Phase: Phase I

Status: In follow-up (non-recruiting)

CARGO
Immunotherapy using CAR T-cells to target EGFRvIII for relapsed/refractory adult Glioblastoma

In the CARGO trial we intend to treat glioblastoma patients with a form of CAR-T cells called CARGO-T cells if standard treatment has failed or their cancer has returned.

Area: Advanced therapies

Phase: Phase I

Status: Active (recruiting)

CARMIGO
Chimeric Antigen Receptor (CAR)-T cells to target GD2 for Diffuse Midline Glioma (DMG)

A single centre, open label, phase 1 trial using the continual reassessment method (CRM) to evaluate the safety and optimal biologic dose of an Advanced Therapy Investigational Medicinal Product (ATIM [...]

Area: Advanced therapies

Phase: Phase I

Status: Active (recruiting)

CAROUSEL
Immunotherapy using CAR T-cells to target CD19 for relapsed/refractory CD19+ Primary CNS Lymphoma

A single centre, non-randomised, open label phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in patients 16 years and above with relapsed/refractory CD19+ Primar [...]

Area: Advanced therapies

Phase: Phase I

Status: In follow-up (non-recruiting)

CARPALL
Immunotherapy with CD19+CD22 CAR redirected T-cells for high risk/relapsed paediatric CD19+ and CD22+ acute lymphoblastic leukaemia

A multi-centre, non-randomised, open label phase I clinicaltrial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults with high risk, relapsed CD19+ and CD22+ [...]

Area: Advanced therapies

Phase: Phase I

Status: Active (recruiting)

CARPERS
Determining the mechanisms of loss of CAR-T cell persistence

CARPERS is an observational study aiming to analyse CAR-T cell persistence over time. It will be offered to patients with CD19-positive acute lymphoblastic leukaemia who will receive the commercially [...]

Area: Advanced therapies

Phase: Observational trials

Status: Active (recruiting)

CD-19TPALL
Immunotherapy with CD19? gene modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia

a multi-site, non-randomised, phase I/II, paediatric trial with 2 arms. The Advanced Therapy Medicinal product (ATMP) tested in the study is donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) tran [...]

Area: Advanced therapies

Phase: Phase I/II

Status: Archived

COBALT
Evaluation of CAR19 T-cells as an optimal bridge to allogeneic transplantation.

Single centre, single arm dose-escalation phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults with resistant or relapsed DLBCL. The ATIMP tested in this s [...]

Area: Advanced therapies

Phase: Phase I

Status: Closed

GLIMPS
Glioma targeting IL13RA2/IL-15 multi-modular CAR T paediatric study

A single centre, open label, phase 1 trial using the continual reassessment method (CRM) to evaluate the safety and optimal biologic dose of IL-15/06B5 CAR T cells in patients aged 2-16 years with IL1 [...]

Area: Advanced therapies

Phase: Phase I

Status: Active (recruiting)

ICAT
Adoptive Immunotherapy with CD25/71 allodepleted donor T cells to improve immunity after unrelated donor stem cell transplant.

ICAT is a multi-centre randomised phase II trial in adult patients with an underlying haematological malignancy undergoing unrelated donor peripheral blood stem cell transplant with Alemtuzumab-based [...]

Area: Advanced therapies

Phase: Phase II

Status: Closed

ITREC
Immunotherapy with Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease after Solid Organ Transplant

ITREC is a multi-site, non-randomised phase I trial in children and adults with Post Transplant Lymphoproliferative Disease (PTLD) after solid organ transplant. The Advanced Therapy Investigational Me [...]

Area: Advanced therapies

Phase: Phase I

Status: In follow-up (non-recruiting)

MAGNETO
Multi-modular Chimeric Antigen Receptor targeting GD2 in Neuroblastoma

A single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and teenagers aged 1-16 years with relapsed or refractor [...]

Area: Advanced therapies

Phase: Phase I

Status: Active (recruiting)

MCARTY
An open label, Phase 1 study evaluating the activity of Modular CAR T for myeloma

Phase1 rolling 6 trial design evaluating safety of a novel BCMA CAR alone (D8 CAR Tcells) and of CAR T cells co-expressing BCMA CAR and a CD19 CAR (D8/CAT CAR Tcells) in patients with relapsed/ refrac [...]

Area: Advanced therapies

Phase: Phase I

Status: In follow-up (non-recruiting)

MIGHTY
Multi-modular Chimeric Antigen Receptor T cells tarGeting B7-H3 in children, Teenage & Young adult sarcoma (Rhabdomyosarcoma (RMS), Ewing’s Sarcoma (EWS) and Desmoplastic Small Round Cell Tumour (DSRCT))

A multi-centre, open label, phase 1 trial using the continual reassessment method (CRM) to evaluate the safety and optimal biologic dose of dTBRII/hBRCA84D CAR T cells in patients with relapsed or ref [...]

Area: Advanced therapies

Phase: Phase I

Status: Active (recruiting)

TACTICAL
Targeted stromal cells expressing TRAIL as a therapy for lung cancer

Phase I:Single site dose de-escalation design with a modified Bayesian continual reassessment method (mCRM) to estimate the recommended Phase II dose (RP2D) of MSCTRAIL in combination with pemetrexed/ [...]

Area: Advanced therapies

Phase: Phase I/II

Status: In follow-up (non-recruiting)